Vertex Pharmaceutic (VRTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 03-2012 | 12-2011 | 09-2011 | 06-2011 | 03-2011 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 87,876 | 41,179 | -146,962 | -375,414 | -176,096 |
| Depreciation Amortization | 8,560 | 35,041 | 25,317 | 17,567 | 8,858 |
| Income taxes - deferred | -2,281 | -7,501 | -18,244 | 9,330 | 0 |
| Accounts receivable | -49,093 | -170,606 | -433,132 | -83,714 | 6,922 |
| Accounts payable and accrued liabilities | -1,400 | 37,468 | 12,103 | 30,147 | -1,066 |
| Other Working Capital | -121,010 | -192,164 | -449,210 | -135,254 | -60,953 |
| Other Operating Activity | 80,264 | 400,318 | 650,200 | 134,515 | 35,707 |
| Operating Cash Flow | $2,916 | $143,735 | $-359,928 | $-402,823 | $-186,628 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -6,155 | -34,595 | -25,266 | -15,281 | -4,850 |
| Net Acquisitions | N/A | -60,000 | -60,000 | -60,000 | N/A |
| Purchase Of Investment | -403,395 | -721,728 | -251,089 | -135,459 | -124,996 |
| Sale Of Investment | 183,987 | 1,016,040 | 923,123 | 788,029 | 536,362 |
| Other Investing Activity | -6,139 | 12,695 | 13,420 | 1,453 | -564 |
| Investing Cash Flow | $-231,702 | $212,412 | $600,188 | $578,742 | $405,952 |
| Cash Flows From Financing Activities | |||||
| Debt Repayment | 0 | -155,000 | -50,000 | -50,000 | -50,000 |
| Common Stock Issued | 21,298 | 124,862 | 108,742 | 88,673 | 33,643 |
| Other Financing Activity | 227 | -94,100 | 0 | 0 | 0 |
| Financing Cash Flow | $21,525 | $-124,238 | $58,742 | $38,673 | $-16,357 |
| Exchange Rate Effect | -136 | 214 | 346 | 406 | 372 |
| Beginning Cash Position | 475,320 | 243,197 | 243,197 | 243,197 | 243,197 |
| End Cash Position | 267,923 | 475,320 | 542,545 | 458,195 | 446,536 |
| Net Cash Flow | $-207,397 | $232,123 | $299,348 | $214,998 | $203,339 |
| Free Cash Flow | |||||
| Operating Cash Flow | 2,916 | 143,735 | -359,928 | -402,823 | -186,628 |
| Capital Expenditure | -6,155 | -34,595 | -25,266 | -15,281 | -4,850 |
| Free Cash Flow | -3,239 | 109,140 | -385,194 | -418,104 | -191,478 |